Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 2/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.44 |
| ▸ | GPR35 | Q9HC97 | 9/20 | 0.44 |
| ▸ | PTPN1 | P18031 | 4/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.33 |
| ▸ | PTPRC | P08575 | 1/20 | 0.32 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Succinimide SCHEMBL4972452 | 0.88 | CYP3A4 (0.41) | CYP3A4CYP2D6KCNH2GPR35PTPN1 | |
| SCHEMBL5228048 | 0.84 | ALDH1A1 (0.44) | CYP3A4CYP2D6KCNH2MAPTKMT2A | |
| SCHEMBL5007159 | 0.78 | CYP3A4 (0.39) | CYP3A4CYP2D6KCNH2MAPTKMT2A | |
| SCHEMBL4973028 | 0.76 | CYP3A4 (0.42) | CYP3A4CYP2D6KCNH2MAPT | |
| SCHEMBL2109577 | 0.72 | CYP3A4 (0.34) | CYP3A4CYP2D6KCNH2 | |
| Hydrochloric Acid SCHEMBL27660461 | 0.71 | CYP3A4 (0.33) | CYP3A4CYP2D6KCNH2 | |
| SCHEMBL2727696 | 0.69 | GPR35 (0.66) | GPR35PTPN1MAPTKMT2APKM | |
| SCHEMBL4753776 | 0.69 | GPR35 (0.68) | GPR35PTPN1PKMNPSR1RXFP1 | |
| SCHEMBL4972435 | 0.67 | KMT2A (0.41) | GPR35MAPTKMT2APKMNPSR1 | |
| SCHEMBL25195925 | 0.66 | GPR35 (0.53) | GPR35MAPTKMT2APKMNPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2008115912-A1 | REGIO-SPECIFIC SYNTHESIS OF 4-BROMO-3-METHYL-5-PROPOXY-THIOPHENE-2-CARBOXYLIC ACID | SANOFI-AVENTIS (FR) | 2008-09-25 | — | — | WO | claimed |
| WO-2008109786-A2 | REGIO-SELECTIVE ULLMANN SYNTHESIS OF 4-BROMO-3-METHYL-5-PROPOXY-THIOPHENE-2-CARBOXYLIC ACID | SANOFI-AVENTIS (FR) | 2008-09-12 | — | — | WO | claimed |
| EP-2483243-B1 | SYNTHESIS OF (4-FLUORO-3-PIPERIDIN-4-YL-BENZYL)-CARBAMIC ACID TERT-BUTYL ESTER AND INTERMEDIATES THEREOF | SANOFI AVENTIS US LLC (US) | 2015-03-18 | — | — | EP | disclosed |
| US-8633321-B2 | Synthesis of (4-fluoro-3-piperidin-4-yl-benzyl)-carbamic acid tert-butyl ester and intermediates thereof | SANOFI-AVENTIS U.S. LLC (US) | 2014-01-21 | — | — | US | disclosed |
| US-8633321-B2 | Synthesis of (4-fluoro-3-piperidin-4-yl-benzyl)-carbamic acid tert-butyl ester and intermediates thereof | SANOFI-AVENTIS U.S. LLC (US) | 2014-01-21 | — | — | US | disclosed |
| EP-2516428-A1 | TROPINONE BENZYLAMINES AS BETA-TRYPTASE INHIBITORS | SANOFI (FR) | 2012-10-31 | — | — | EP | disclosed |
| US-20120238600-A1 | TROPINONE BENZYLAMINES AS BETA-TRYPTASE INHIBITORS | SANOFI (FR) | 2012-09-20 | — | — | US | disclosed |
| US-20120184745-A1 | SYNTHESIS OF (4-FLUORO-3-PIPERIDIN-4-YL-BENZYL)-CARBAMIC ACID TERT-BUTYL ESTER AND INTERMEDIATES THEREOF | SANOFI-AVENTIS U.S. LLC (US) | 2012-07-19 | — | — | US | disclosed |
| US-20120184745-A1 | SYNTHESIS OF (4-FLUORO-3-PIPERIDIN-4-YL-BENZYL)-CARBAMIC ACID TERT-BUTYL ESTER AND INTERMEDIATES THEREOF | SANOFI-AVENTIS U.S. LLC (US) | 2012-07-19 | — | — | US | disclosed |
| WO-2011087652-A1 | TROPINONE BENZYLAMINES AS BETA-TRYPTASE INHIBITORS | SANOFI (FR) | 2011-07-21 | — | — | WO | disclosed |
| WO-2011037947-A1 | SYNTHESIS OF (4-FLUORO-3-PIPERIDIN-4-YL-BENZYL)-CARBAMIC ACID TERT-BUTYL ESTER AND INTERMEDIATES THEREOF | SANOFI-AVENTIS U.S. LLC (US) | 2011-03-31 | — | — | WO | disclosed |
| WO-2008115912-A1 | REGIO-SPECIFIC SYNTHESIS OF 4-BROMO-3-METHYL-5-PROPOXY-THIOPHENE-2-CARBOXYLIC ACID | SANOFI-AVENTIS (FR) | 2008-09-25 | — | — | WO | disclosed |
| WO-2008109786-A2 | REGIO-SELECTIVE ULLMANN SYNTHESIS OF 4-BROMO-3-METHYL-5-PROPOXY-THIOPHENE-2-CARBOXYLIC ACID | SANOFI-AVENTIS (FR) | 2008-09-12 | — | — | WO | disclosed |
| WO-2008109786-A2 | REGIO-SELECTIVE ULLMANN SYNTHESIS OF 4-BROMO-3-METHYL-5-PROPOXY-THIOPHENE-2-CARBOXYLIC ACID | SANOFI-AVENTIS (FR) | 2008-09-12 | — | — | WO | disclosed |
| US-20070142435-A1 | [4-(5-Aminomethyl-2-fluoro-phenyl)-piperidin-1-yl]-(4-bromo-3-methyl-5-propoxy-thiophen-2-yl)-methanone hydrochloride as an inhibitor of mast cell tryptase | AVENTIS PHARMACEUTICALS INC. (US) | 2007-06-21 | — | — | US | disclosed |
| US-20070142435-A1 | [4-(5-Aminomethyl-2-fluoro-phenyl)-piperidin-1-yl]-(4-bromo-3-methyl-5-propoxy-thiophen-2-yl)-methanone hydrochloride as an inhibitor of mast cell tryptase | AVENTIS PHARMACEUTICALS INC. (US) | 2007-06-21 | — | — | US | disclosed |
| US-20070142435-A1 | [4-(5-Aminomethyl-2-fluoro-phenyl)-piperidin-1-yl]-(4-bromo-3-methyl-5-propoxy-thiophen-2-yl)-methanone hydrochloride as an inhibitor of mast cell tryptase | AVENTIS PHARMACEUTICALS INC. (US) | 2007-06-21 | — | — | US | disclosed |
| EP-1737848-A1 | [4-(5-AMINOMETHYL-2-FLUORO-PHENYL)-PIPERIDIN-1-YL]-(4-BROMO-3-METHYL-5-PROPOXY-THIOPHEN-2-YL)-METHANONE HYDROCHLORIDE AS AN INHIBITOR OF MAST CELL TRYPTASE | Aventis Pharmaceuticals Inc. (US) | 2007-01-03 | — | — | EP | disclosed |
| WO-2005097780-A1 | [4-(5-AMINOMETHYL-2-FLUORO-PHENYL)-PIPERIDIN-1-YL]-(4-BROMO-3-METHYL-5-PROPOXY-THIOPHEN-2-YL)-METHANONE HYDROCHLORIDE AS AN INHIBITOR OF MAST CELL TRYPTASE | AVENTIS PHARMACEUTICALS INC. (US) | 2005-10-20 | — | — | WO | disclosed |
| WO-2005097780-A1 | [4-(5-AMINOMETHYL-2-FLUORO-PHENYL)-PIPERIDIN-1-YL]-(4-BROMO-3-METHYL-5-PROPOXY-THIOPHEN-2-YL)-METHANONE HYDROCHLORIDE AS AN INHIBITOR OF MAST CELL TRYPTASE | AVENTIS PHARMACEUTICALS INC. (US) | 2005-10-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120238600-A1 | TROPINONE BENZYLAMINES AS BETA-TRYPTASE INHIBITORS | TPSAB1, TPSB2, TPSD1 | CYP3A4 380/4885CYP2D6 248/4885KCNH2 1248/4885 |
| US-20070142435-A1 | [4-(5-Aminomethyl-2-fluoro-phenyl)-piperidin-1-yl]-(4-bromo-3-methyl-5-propoxy-thiophen-2-yl)-methanone hydrochloride as an inhibitor of mast cell tryptase | CMA1, TPSAB1, TPSB2 | CYP3A4 298/4885CYP2D6 59/4885KCNH2 677/4885 |
| US-20120184745-A1 | SYNTHESIS OF (4-FLUORO-3-PIPERIDIN-4-YL-BENZYL)-CARBAMIC ACID TERT-BUTYL ESTER AND INTERMEDIATES THEREOF | TBC1D5, TBC1D15, TERT | CYP3A4 56/4885CYP2D6 227/4885KCNH2 585/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.